BDXBDX
US • —
$151.33
P/E
38.42
PEG
—
FCF Yield
—
Rev Growth YoY
+2.4% YoY
Gross Margin
47.0%
Health Score
6/10
D/E Ratio
0.76
Confidence
MEDIUM
Business Snapshot
BDX operates as a global medical technology company, primarily focused on medical devices, laboratory equipment, and diagnostic systems. The company serves healthcare institutions and clinical laboratories, holding a well-established position in the medical devices and supplies market. As market capitalisation is not available, its precise market cap tier cannot be determined from this data. A defining characteristic is its diversified product base spanning medication management and infection prevention, though recent transparency on quarterly segment details is limited in this dataset.
Financial Health
Gross margin stands at 47.0%, though without prior-year comparison, the trend direction cannot be assessed. Net margin is 5.3%, a relatively thin figure that limits earnings retention on each dollar of revenue...
Risk Assessment
- VALUATION — P/E of 38.42x is 75% above the sector average of 22x, indicating a substantial premium that expects high future growth.
- EARNINGS QUALITY — earnings declined 24.8% year-over-year, a significant deterioration that contrasts with the elevated valuation multiple.
- FCF / CASH BURN — free cash flow is unavailable or negative, preventing cash generation assessment and raising uncertainty about underlying financial health.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Gross margin stands at 47.0%, though without prior-year comparison, the trend direction cannot be assessed. Net margin is 5.3%, a relatively thin figure that limits earnings retention on each dollar of revenue. The balance sheet appears adequately positioned with a debt/equity ratio of 0.76x and a current ratio of 1.11x, indicating moderate leverage and sufficient short-term liquidity. Return on equity is low at 4.5%, reflecting subdued profitability relative to shareholder equity. Free cash flow data is unavailable, preventing a direct assessment of cash generation capacity. Overall financial health is adequate but not robust, with thin margins and low ROE suggesting limited room for aggressive reinvestment or dividend growth.
- VALUATION — P/E of 38.42x is 75% above the sector average of 22x, indicating a substantial premium that expects high future growth. - EARNINGS QUALITY — earnings declined 24.8% year-over-year, a significant deterioration that contrasts with the elevated valuation multiple. - FCF / CASH BURN — free cash flow is unavailable or negative, preventing cash generation assessment and raising uncertainty about underlying financial health. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives